Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients
Crossref DOI link: https://doi.org/10.1007/s00520-016-3347-3
Published Online: 2016-08-08
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Volovat, Constantin
Bondarenko, Igor
Gladkov, Oleg
Buchner, Anton
Lammerich, Andreas
Müller, Udo
Bias, Peter
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R&D, Inc.
License valid from 2016-08-08